Jiang Ming, Wang Xing-Chuan
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2013 Oct;27(5):363-5.
To study the efficacy of early, enough methylprednisone combined with immunoglobulin in treatments of severe hand-foot-mouth disease.
568 patients of severe hand-foot-mouth disease involved were randomized into group A and group B. Patients of both groups all accepted symptomatic treatment, supportive therapy and the treatment of control intracranial pressure. And patients in group A received the treatment of early, enough methylprednisone combined with immunoglobulin, whereas patients in group B received conventional therapy. RESULTS; Curative rate of group A was better than that of group B, otherwise incidence rate of critical illness was less than that of group B. The control time of fever, erythra, neurological symptoms, features of pneumonia and increased leukocyte of group A was shorter than that of group B, and no more recent or Long-term treatment-related adverse reaction in group A.
Early, enough methylprednisone combined with immunoglobulin is effective, safe in treating severe hand-foot-mouth disease, and worthy to recommand its clinical use.
探讨早期足量甲基泼尼松联合免疫球蛋白治疗重症手足口病的疗效。
将568例重症手足口病患者随机分为A组和B组。两组患者均接受对症治疗、支持治疗及控制颅内压治疗。A组患者接受早期足量甲基泼尼松联合免疫球蛋白治疗，而B组患者接受常规治疗。结果：A组治愈率高于B组，重症发病率低于B组。A组发热、皮疹、神经症状、肺炎表现及白细胞升高的控制时间短于B组，且A组近期及远期均未出现与治疗相关的不良反应。
早期足量甲基泼尼松联合免疫球蛋白治疗重症手足口病有效、安全，值得临床推广应用。
